Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion on the Ulcerative Colitis Landscape - Where does PN-10943 fit in against Tofacitinib, Ozanimod, Etrolizumab, and Entyvio?

Ticker(s): PTGX, PFE, RHHBY, CELG, TKPYY

Who's the expert?

Name: Dr Francis Farraye - MD | MSc

Institution: Boston University

  • Clinical Director, Section of Gastroenterology, Director, Inflammatory Bowel Disease Center at Boston Medical Center and Professor of Medicine at BU School of Medicine.
  • Currently treats 60-70 ulcerative colitis patients per month.
  • Special Interests in Ulcerative colitis, Crohn's disease, Inflammatory Bowel Disease

Interview Goal
To get a better understanding of the safety and efficacy of the UC drugs such as Tofacitinib, Ozanimod, Etrolizumab and Entyvio. This call will examine the market potential of PN-10943 after PTG-100 reissued the Independent blinded re-read of endoscopies relating to the PROPEL trial.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.